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Multifunctional, histidine-tagged polymers:
antibody conjugation and signal amplification†
Yichuan Zhang, ‡ab Alessia Gambardella,‡a Muhammed Üçüncü, ac
Jin Geng, ab Jessica Clavadetscher,a Mark Bradley *a and
Annamaria Lilienkampf *a
A polymer scaffold, with multiple reactive centres, was synthesised
by RAFT polymerisation and conjugated to the antibody herceptin.
A hexahistidine RAFT agent enabled the rapid and simple purification
of polymer–protein conjugates, while the tetrazine conjugation
strategy allows myriad cargos to be attached and amplified.
The ability to amplify reporter signals and cargos is important in a
number of areas ranging from fluorescent imaging to radio-
therapy and is of particular importance with low abundance
targets. Several signal enhancement methods have been developed
with numerous techniques associated with the polymerase chain
reaction and variants.1 Non-nucleic acid based amplification
methods include horseradish peroxidase-driven signal amplifica-
tion of tyramide-conjugates2 or luminol,3 and alkaline phosphatase
driven amplification.4 Although these enzyme-based amplification
methods work well, they typically require the use of secondary
antibodies and bespoke substrates, with colorimetric or fluorescent
outputs often able to diffuse away from the site of generation. Non-
enzymatic fluorescence amplification techniques include e.g. the
recruitment of antibody-GFP fusion proteins to a target protein
tagged with multiple copies of the antibody epitope,5 Avidin-
conjugated viral capsids loaded with dyes for the detection of
biotinylated targets,6 and biological self-assembly of biotin and
streptavidin surface engineered quantum dots.7
Synthetic polymers are an attractive approach to biomolecule
labelling and fluorescence or mass-tag signal amplification.8
Conjugation of polymers to proteins can be categorised as
‘‘grafting-from’’ and ‘‘grafting-to’’ approaches,9 the former start-
ing with the formation of a ‘‘macro-activator’’ (i.e., linkage of an
initiator or a chain transfer agent to a protein), followed by
polymerisation; however, this approach is limited by the need to
avoid protein denaturation and the restricted choice of suitable
functional monomers.10 The ‘‘grafting-to’’ approach uses
pre-synthesised polymers for bioconjugation but suffers from
complications, such as how to separate conjugated proteins
from non-conjugated materials.11
Here, we report a rapid amplification approach, based on
poly(acrylamide)–antibody conjugates bearing norbornene
reactive centres for both ‘‘switch-on’’ of quenched tetrazine-
linked fluorophores and cargo amplification in the form of
metal ions (Fig. 1). The polymers were synthesised through
reversible addition–fragmentation chain transfer (RAFT) poly-
merisation, using the synthesised chain transfer agent 2 that
contained the ubiquitous hexahistidine tag (His-Tag), designed
to allow rapid polymer–antibody conjugate purification by
metal affinity chromatography. Upon treatment with a
quenched BODIPY–tetrazine conjugate, rapid ‘‘switch-on’’ and
amplification in fluorescence were observed.
Five polymers with different molecular weights and densities
of the norbornene reactive centres were synthesised (P1–P5) to
explore how composition affected conjugation, antibody
binding affinity, and the level of cargo amplification (Fig. 2a).
N,N-Dimethylacrylamide (DMA) was used due to its low cytotoxi-
city and the high water solubility of its polymers,12 with the
norbornene-based acrylamide 1 (Scheme S1, ESI†) providing the
site for tetrazine ligation. The polymers were efficiently synthe-
sised by RAFT polymerisation with the desired molecular
weights (7–30 kDa) with polydispersities between 1.2–1.8 (Table
S1 and Fig. S1, ESI†) using a His-Tag-RAFT agent 2 (synthesised
on solid-phase13 in high yield/purity, Scheme S2, ESI†), which
allowed the widely used method of metal ion affinity chromato-
graphy to be applied to polymer-conjugate purification.
To achieve simultaneous ‘‘switch-on’’ and amplification of
fluorescence by the polymer–protein conjugates, two fluorogenic
BODIPY–tetrazines were synthesised (Fig. 2b). Tetrazine-quenched
fluorophores, that are activated via an inverse electron-demand
Diels–Alder reaction (INVDA), have found use in fluorescent
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imaging,14–18 allowing direct target visualisation without extensive
washing steps. Tz1 was synthesised as reported previously,14
whereas the published route to Tz215 could not be reproduced
and instead was synthesised from 3-formylbenzonitrile, via the
tetrazine aldehyde S9,16 which was treated with 2,4-dimethyl-
pyrrole, followed by oxidation with DDQ and complexation with
BF3OEt2 to give the BODIPY–tetrazine Tz2 in high yield (Scheme
S3, ESI†).17 The metal chelating tetrazine Tz3 was synthesised
by coupling the DOTA–NHS ester to an amino-functionalised
tetrazine,19 followed by Cu(II) loading (Scheme S4, ESI†).
The reactivity of the norbornene-decorated polymer P1
(12 mM) with the tetrazines Tz1 and Tz2 (1 mM) was investigated
by monitoring the time-dependent increase in fluorescence,
triggering fluorescence increases of 21 and 9-fold respectively,
in PBS after 30 min (Fig. S3 and S4, ESI†). However, stability
studies showed that although Tz1 and Tz2 were robust in PBS
and serum-free media, Tz2 underwent undesired tetrazine
hydrolysis in serum, while in contrast, Tz1 showed good
stability and was thus used in preference for all investigations
(Fig. S5, ESI†).
The antibody herceptin facilitates tyrosine kinase receptor
HER2 degradation and is used clinically to treat aggressive
breast cancer,20 and was used here to demonstrate both cell
labelling21 and cargo amplification. Polymers conjugated to
herceptin (P1-Her–P5-Her) were purified in 45–88% yields
utilising the His-Tag (Fig. 2a and Table S2, ESI†), with SDS
PAGE showing successful conjugation (Fig. S9, ESI†). When
P1-Her was treated with tetrazine Tz1 (Fig. 2a), intense fluores-
cent labelling of the antibody resulted, with selectivity between
the polymer-tagged antibody and the unmodified variant
observed (Fig. 3a, lane 2 vs. 4). In addition, SDS-PAGE analysis
indicated that the majority of polymer conjugation took place on
the heavy chains of the antibody. The influence of the polymers
on the antibody’s binding affinity was investigated by flow
cytometry analysis of the labelling efficiency of the polymer–
antibody conjugates on HER2 receptor positive breast cancer
cells (SK-BR-3) with BODIPY-P1-Her, BODIPY-P2-HER and
BODIPY-P3-Her and BODIPY-Her. Incubation of SK-BR-3 cells
with small molecule labelled BODIPY-Her (Scheme S5, ESI†)
resulted in rapid labelling of the cells with fluorescence saturation
of cells observed after 2 h. Similar labelling and fluorescence
saturation of cells was also observed by polymer conjugated
antibodies BODIPY-P2-Her and BODIPY-P3-Her, whereas
BODIPY-P1-Her showed slower labelling with fluorescence
saturation reached after 4 h incubation (Fig. 3b). MCF-7 cells,
which do not express the HER2 receptor, showed no significant
changes in fluorescence intensity when incubated with the
polymer–herceptin conjugates (Fig. S10, ESI†). None of the
polymer–antibody conjugates (P1-Her to P5-Her), BODIPY-Her
or Tz1 showed cellular toxicity at 10 nM, 10 nM and 1 mM,
respectively (Fig. S11, ESI†).
The fluorescence ‘‘turn-on’’ and signal amplification with
the polymer–antibody conjugates and tetrazine Tz1 was demon-
strated in live SK-BR-3 cells by flow cytometry and microscopy
(Fig. 3c and d). Cells treated with BODIPY-Her (4 h, 10 nM)
showed a moderate increase in fluorescence intensity; however,
treatment with the conjugates P1-Her to P5-Her (4 h, 10 nM),
followed by the quenched fluorophore Tz1 (30 min, 1 mM)
Fig. 1 Signal amplification using a polymer–protein conjugate. The antibody herceptin was conjugated to a polymer scaffold that carried multiple
norbornenes (for signal amplification via tetrazine ligation) and was synthesised using a hexahistidine tagged-RAFT agent. Subsequent treatment with a
tetrazine-quenched fluorophore or a metal-bearing tetrazine, ‘‘switches-on’’ and/or amplifies the signal.
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Fig. 2 (a) Synthesis of the multifunctional polymers P1–P5 and the ratios of 1, 2 and DMA found in the synthesised polymers (based on 1H NMR analysis).
All polymers were synthesised as random copolymers (see ESI,† Table S1 for full characterisation). Polymer synthesis was followed by their antibody
conjugation (10 eq. polymer per antibody added) and metal-affinity chromatography purification of the polymer–antibody conjugates (P1-Her–P5-Her)
and subsequent INVDA mediated dequenching to give the fluorescent conjugates. The NHS-conjugation strategy produces heterogenous polymer–
antibody population, with multiple conjugation sites possible; however, only one modification site on the antibody is shown for clarity. (b) The tetrazines
explored for signal amplification.
Fig. 3 (a) SDS-PAGE showing successful conjugation and fluorescence ‘‘switch-on’’. Lane 1 herceptin; lane 2 herceptin (2.5 mM) incubated with Tz1
(25 mM); lane 3 P1-Her and lane 4 P1-Her (2.5 mM) incubated with Tz1 (25 mM) (reaction mixtures were purified using centrifugal size exclusion filters prior
to analysis). (b) Polymer–herceptin conjugate labelling of SK-BR-3 cells (quantified by flow cytometry with fluorescence intensity normalised to
fluorescence saturated cells, n = 3) compared to the traditional small molecule labelled herceptin BODIPY-Her (Scheme S5, ESI†). (c) Fluorescence
intensity of HER2 receptor positive SK-BR-3 cells treated first with the polymer–herceptin conjugates (10 nM) followed by Tz1 (1 mM) (normalised to cells
treated with P3-Her followed by Tz1). The increase in fluorescence intensity between BODIPY-Her and BODIPY-labelled P1–P5-Her was 45, 10, 83,
6 and 83-fold, respectively. Inset: The flow cytometry histograms of SK-BR-3 cells treated with BODIPY labelled herceptin BODIPY-Her or Tz1, or the
polymer–antibody conjugate P1-Her followed by Tz1 (green). Data were analysed using one-way ANOVA with Dunnett post-test (ns, not significant,
***P o 0.001, ****P o 0.0001). (d) Confocal fluorescence microscopy images of SK-BR-3 cells treated with BODIPY-labelled herceptin BODIPY-Her
(10 nM), and polymer–antibody conjugates P1-Her and P3-Her (10 nM) followed by Tz1 (1 mM). The cell nucleus was stained with Hoechst 33342 (blue,
lex/em = 353/483 nm) and the plasma membrane stained with CellMaskt Deep Red (red, lex/em = 649/666 nm). ‘‘Switched-on‘‘ BODIPY from Tz1 is
shown in green (lex/em = 488/512 nm). Scale bar = 10 mm. The norbornene content and monomer ratios for P1–P5 (based on
1H NMR analysis) are given
in Fig. 2.
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resulted in remarkable increases in cellular fluorescence
(83-fold increase for P3-Her and P5-Her, compared to
BODIPY-Her). The fluorescence intensity could be tuned by
either changing the molecular weight of the polymers (45, 10
and 83-fold increases for P1-Her, P2-Her and P3-Her, respec-
tively) or the density of the reactive centres (6 and 83-fold
increase for P4-Her and P5-Her, bearing 2.8 and 18 norbornes
per polymer chain, respectively). Confocal microscopy images
of the cells treated with P1-Her and P3-Her, which had different
numbers of reactive centres (8 vs. 21), followed by Tz1 showed
much brighter fluorescence (lex/em = 488/512 nm) than BODIPY-
Her treated cells, although with similar cellular localisations,
i.e., cytoplasma and membrane (Fig. 3d and Fig. S12, ESI†).
This amplification method could also be translated to
amplifying the loading density of radioisotopes.22 As a proof
of concept, P5-Her was pre-labelled with Tz3 (Fig. 2a, Fig. S11
and Scheme S6, ESI†) bearing Cu(II) on a DOTA ligand (copper
was used as a model as 64Cu is widely used in nuclear
medicine23). The amplified metal loading on SK-BR-3 cells
was confirmed by inductively coupled plasma-mass spectro-
metry (ICP-MS) where the Cu(II) loaded polymer–antibody
conjugate Cu-P5-Her showed a 6-fold higher copper loading
(1.6 pg per cell) in comparison to the conventionally radiola-
belled antibody Cu-Her (Fig. S14 and Scheme S7, ESI†).
In summary, a linear poly(acrylamide) scaffold bearing
norbornenes and a His-Tag was synthesised, conjugated to a
clinically used antibody herceptin, and used for fluorescence
and metal amplification. Compared to the standard small mole-
cule fluorophore labelled antibody, the polymer–antibody con-
jugates gave up to an 83-fold increase in fluorescence without
affecting antibody binding. This approach of receptor targeted
polymer conjugates enables simultaneous ‘‘switch-on’’ and
amplification of fluorescent signal with possible contributions
to fluorescence-guided surgery and other fluorescence-based
applications, especially those where signals are inherently weak
due to low numbers of receptors. The approach was applied to
the amplification of metal loading with possible uses in nuclear
medicine, but the designed polymer scaffold would also enable
the ‘‘multiplication’’ of other molecules (e.g. drugs). The new
His-Tag-RAFT agent provides a powerful new approach to access
various functional polymers with an endogenous purification
handle to enable the rapid and simple purification of both
‘‘graft-to’’ or ‘‘graft-from’’ polymer-conjugates.
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